IP Library Granted Patent US 8,986,984
Granted Patent B2
US 8,986,984 · App. 12/618,664 · Granted Mar 24, 2015

Method of propagating cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,986,984
App. No.
12/618,664
Granted
Mar 24, 2015
Kind
B2
Abstract

A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.

Claims (18)

1. A method of propagating exogenous cells in a placental bioreactor comprising:

processing an intact placenta to drain umbilical cord blood,

irradiating the endogenous cells of the intact placenta such that no or substantially no viable placental cells remain,

introducing exogenous cells into the intact placenta, and

incubating the intact placenta with the exogenous cells so that the exogenous cells are propagated.

2. The method of claim 1 wherein the irradiating step is performed with irradiation selected from electromagnetic, ultra-violet, X-ray, gamma-, and beta -radiation.

3. The method of claim 1 wherein the exogenous cells are stem cells.

4. The method of claim 3 wherein the stem cells are hemopoietic pluripotent stem cells.

5. The method of claim 1 wherein the exogenous cells are stimulated to produce bioactive molecules.

6. The method of claim 5 wherein the bioactive molecules are collected prior to collecting the propagated exogenous cells.

7. The method of claim 1 wherein the exogenous cells are stimulated to propagate by introducing factors selected from cytokines, hormones, promoters, repressors, proteins, nucleic acids, viruses, and immunogens.

8. The method of claim 5 , wherein the bioactive molecules are selected from immunoglobulins, hormones, and growth factors.

9. The method of claim 1 , wherein said placenta is perfused prior to the step of irradiating.

10. The method of claim 9 , wherein the placenta is perfused with a perfusion solution that is an anticoagulant perfusion solution.

11. The method of claim 1 , further comprising the step of perfusing the placenta with nutrient perfusion solution following the step of irradiating.

12. The method of claim 1 , further comprising collecting the propagated exogenous cells.

13. The method of claim 9 , wherein the placenta is perfused with a perfusion solution, further comprising the step of collecting said perfusion solution and stem cells in said perfusion solution, wherein said stem cells comprise CD34+ cells or CD34−cells.

14. The method of claim 9 , further comprising the step of perfusing the placenta with nutrient perfusion solution following the step of irradiating.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2010
From: HARIRI, ROBERT J.
To: ANTHROGENESIS CORPORATION
Reel/Frame 024631/0636 →